Everything drug pricing and policy, every day
Plus the drug industry gets a big appeals court win in the ongoing battle to set rules around 340B contract pharmacies
And a price war of sorts is emerging as Arrowhead and Ionis prepare to enter a large CV disease market
And a new paper makes clear how quickly Chinese biopharma has risen
That’s notable, because, before yesterday, prices had not been publicly disclosed for a single med approved in 2026
And a legal case that seeks to close the 340B “STD loophole” kicks off
And a theory about the drip-drip-drip approach to putting medicines on TrumpRx
